CN1889944A - ErbB2激酶过量表达相关疾病的治疗 - Google Patents

ErbB2激酶过量表达相关疾病的治疗 Download PDF

Info

Publication number
CN1889944A
CN1889944A CNA2004800362204A CN200480036220A CN1889944A CN 1889944 A CN1889944 A CN 1889944A CN A2004800362204 A CNA2004800362204 A CN A2004800362204A CN 200480036220 A CN200480036220 A CN 200480036220A CN 1889944 A CN1889944 A CN 1889944A
Authority
CN
China
Prior art keywords
cancer
cocoa
erbb2
oligomers
polyphenols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800362204A
Other languages
English (en)
Chinese (zh)
Inventor
H·H·施米茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mars Inc
Original Assignee
Mars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mars Inc filed Critical Mars Inc
Publication of CN1889944A publication Critical patent/CN1889944A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800362204A 2003-10-10 2004-10-08 ErbB2激酶过量表达相关疾病的治疗 Pending CN1889944A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51060403P 2003-10-10 2003-10-10
US60/510,604 2003-10-10

Publications (1)

Publication Number Publication Date
CN1889944A true CN1889944A (zh) 2007-01-03

Family

ID=34435110

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800362204A Pending CN1889944A (zh) 2003-10-10 2004-10-08 ErbB2激酶过量表达相关疾病的治疗

Country Status (9)

Country Link
US (1) US20050245601A1 (enExample)
EP (1) EP1670455A4 (enExample)
JP (1) JP2007508316A (enExample)
CN (1) CN1889944A (enExample)
AU (1) AU2004280257A1 (enExample)
CA (1) CA2541548A1 (enExample)
IL (1) IL174763A0 (enExample)
RU (1) RU2006115615A (enExample)
WO (1) WO2005034879A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918844A (zh) * 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006263669B9 (en) * 2005-06-29 2012-12-13 Mars, Incorporated Inducing peripheral blood vessel vasodilation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2004208B1 (en) * 2005-12-23 2017-01-25 Mars, Incorporated Skin protection and improvement
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554645A (en) * 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
CN1159019C (zh) * 1996-04-02 2004-07-28 火星有限公司 可提取物化合物以及其制备方法和用途
US6297273B1 (en) * 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US6207842B1 (en) * 1997-10-09 2001-03-27 Mars Incorporated Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives
US6156912A (en) * 1999-04-09 2000-12-05 Mars, Incorporated 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation
US7015338B1 (en) * 1999-04-15 2006-03-21 Mars Incorporated Synthetic methods for preparing procyanidin oligomers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918844A (zh) * 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗

Also Published As

Publication number Publication date
IL174763A0 (en) 2008-04-13
EP1670455A2 (en) 2006-06-21
JP2007508316A (ja) 2007-04-05
WO2005034879A2 (en) 2005-04-21
RU2006115615A (ru) 2007-11-27
AU2004280257A1 (en) 2005-04-21
EP1670455A4 (en) 2008-10-15
US20050245601A1 (en) 2005-11-03
CA2541548A1 (en) 2005-04-21
WO2005034879A3 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
US9416196B2 (en) Composition for prophylaxis or treatment of vascular or cardiac valvular calcification comprising dipeptidyl peptidase-4 inhibitor
CN101516407B (zh) 改善精氨酸酶水平/活性
CN1436047A (zh) 促进血管健康的组合物和方法
EP3263134A1 (en) Composition for preventing or treating valve calcification, containing dpp-4 inhibitor
US20050245601A1 (en) Treatment of diseases involving ErbB2 kinase overexpression
WO2011108487A1 (ja) 筋萎縮阻害剤
KR20080065593A (ko) 지방세포의 지방 축적을 관리하는 방법
US20050171029A1 (en) Methods and compositions for treating cancer
JP2006516540A (ja) ホメオスタシスを促進するフラバノールおよびプロシアニジン
JP2013173719A (ja) スダチチンを有効成分とする、メタボリックシンドロームの予防及び／又は治療剤
CN109640978B (zh) 以芹菜素、姜黄素及和厚朴酚为有效成分包含的肺癌预防或治疗用药学组合物
CN107148277B (zh) 一种抑制脂肪细胞分化和胰岛素耐受的药物
KR20120058047A (ko) 스핑고신-1-포스페이트（ｓｐｈｉｎｇｏｓｉｎｅ－１－ｐｈｏｓｐｈａｔｅ） 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 예방 및 치료용 약학적 조성물
CN113712950A (zh) 创伤酸在制备抗肥胖药物或抗肥胖保健品中的应用
KR20220071741A (ko) 대두 추출물 및 효소적으로 처리된 루틴, 이의 염, 이의 입체 이성질체, 이의 수화물 또는 이의 용매화물을 유효성분으로 함유하며 미토콘드리아의 활성을 촉진시키며 백색 지방세포로부터 갈색 지방세포로의 형성을 유도하는 항비만 조성물
Nguyen Effects of nacre supplementation on bone loss (induced or natural) in rodent models
EP4461294A1 (en) Lipolytic and antiadipogenic coumarin derivatives
TWI757511B (zh) 乙內醯脲衍生物之用途
US20220313620A1 (en) Composition for preventing and treating tauopathies
CN1758917A (zh) 黄烷醇和矢车菊苷配质促进内环境稳定
WO2026053965A1 (ja) Ａｍｐｋ活性化用組成物、脂肪肝抑制用組成物、肝硬変抑制用組成物、ａｍｐｋ活性化用組成物の製造のための化合物の使用、脂肪肝抑制用組成物の製造のための化合物の使用及び肝硬変抑制用組成物の製造のための化合物の使用
JP2008063279A (ja) 血糖上昇予防・治療剤
KR20220142284A (ko) 네오헤스페리딘 디하이드로칼콘 당전이체를 포함하는 비만 예방, 개선 또는 치료용 조성물
US20090209653A1 (en) Agent for increasing testosterone level
WO2007053639A2 (en) A-type procyanidins and cox-2 expression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication